Nature

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial

Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data are lacking regarding their natural history, associated complications and infusion ...
ascopubs.org

Measurements of 5-FU levels in plasma of patients with gastrointestinal cancer.

Correlation of postoperative CEA trends with survival and patterns of recurrence after hepatectomy for colorectal cancer metastases. Background: 5-fluorouracil (5-FU) 50 years after its first ...
MedPage Today

Study Backs Skipping 5-FU Bolus in Chemo Regimens for Gastrointestinal Cancers

Omitting bolus 5-fluorouracil (5-FU) from combination chemotherapy for gastrointestinal (GI) cancers did not adversely affect survival and was associated with less toxicity, a review of a large ...
Nature

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus ...
Medscape

First Chemo 'Antidote' Cuts Deaths From 5-FU Toxicity

SAN FRANCISCO — The first and only antidote for a chemotherapy overdose appears to be a safe and effective life-saving emergency treatment. The product, uridine triacetate (Vistogard, Wellstat ...
CMAJ

Hyperammonemic encephalopathy after 5-fluorouracil chemotherapy

Hyperammonemic encephalopathy is a rare but potentially life-threatening complication of 5-fluorouracil (5-FU) chemotherapy, most often associated with continuous-infusion regimens. Clinicians should ...